Oramed Pharmaceuticals (NASDAQ:ORMP) appointed Dr. Roy Eldor to the newly created post of chief medical director.
“We are very pleased to welcome Dr. Eldor on board at this pivotal time for Oramed as we head towards a Phase 3 trial for our oral insulin capsule, ORMD-0801,” CEO, Nadav Kidron, said in a statement.
Dr. Eldor will lead Oramed’s clinical development programs, with a specific near-term focus on bringing ORMD-0801 through regulatory approval and to market.
Dr. Eldor is an endocrinologist, internist and researcher with over 20 years of clinical and scientific experience. He is currently director of the Diabetes Unit at the Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center.
